Baystreet.ca RSS Feed http://www.baystreet.ca/rss/MasterRSS.aspx en-us Copyright (c) 2024 Baystreet.ca Inc. All rights reserved. 4/25/2024 5:27:05 PM <![CDATA[MAG Silver "BUY"]]>Thu, 25 Apr 2024 11:59:00 ESThttps://www.baystreet.ca/articles/analyst_ratings.aspx?96957<![CDATA[Miner BHP To Buy Rival Anglo American For $39 Billion]]>Thu, 25 Apr 2024 07:19:00 ESThttps://www.baystreet.ca/articles/commodities.aspx?id=7145Thursday, April 25, 2024


Miner BHP To Buy Rival Anglo American For $39 Billion


Mining giant BHP Group (BHP) has made a $38.90 billion U.S. bid for rival Anglo American (AAL).

Australia-based BHP has made an all-stock offer that would give Anglo American’s ordinary shareholders 0.7097 BHP share for each share of Anglo American that is held.

In a news release, BHP said the acquisition will optimize Anglo American’s “assets and long-term growth potential.”

The combined companies would create the world’s largest copper miner, representing 10% of global output. Anglo American has a huge copper mine in South America.

Mining companies are actively trying to shore up copper supplies ahead of projected shortages and the metal’s key role in the energy transition, say analysts.

The deal would also increase BHP’s diamond sector exposure, given Anglo American’s 85% stake in jewelry retailer De Beers.

The mining industry has experienced an increase in mergers and acquisitions in recent years as companies position themselves for shifting global demand.

It is not immediately clear when the acquisition will be completed.

The stock of BHP is down 3% on news of its bid for Anglo American. Over the last 12 months, BHP’s share price has risen 4% to trade at $59.24 U.S.

Anglo American’s stock is up 12% on news of the deal. In the past year, its stock has gained 2% to trade at $3,084.70 U.S. per share.

]]>
<![CDATA[Navitas Dips on Eve of Shenzhen Conference]]>Thu, 25 Apr 2024 09:41:00 ESThttps://www.baystreet.ca/articles/techinsider.aspx?id=4227Thursday, April 25, 2024

Navitas Dips on Eve of Shenzhen Conference


Navitas Semiconductor (NASDAQ: NVTS) shares fell Thursday, as the company calling itself the industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ silicon carbide (SiC) power semiconductors, announced its participation in forthcoming China Electronic Hotspot Solutions Innovation Summit in Shenzhen this weekend. The summit gathers key players in power semiconductors and associated customer design teams for innovations in EV such as 800 V supercharging, battery management, intelligent connected vehicle electronics, and high-power digital power supplies. 2024 EV OEM attendees include experts from Voyah and Dongfeng.

Jacky Xiao, Navitas’ Technical Marketing Manager, will deliver a keynote titled “High-Frequency On-Board Charger Solutions Based on Hybrid Design of SiC and GaN”, to introduce how Navitas can create more efficient, smaller and lighter on-board charging for EVs. Without compromise, customers can select Navitas’ optimal, feature-rich GaN and SiC power devices in robust, thermally-enhanced TOLL and TOLT packaging, to create hybrid powertrain solutions that deliver faster charging, longer range and lower systems costs.

Navitas’ GaNFast power ICs integrate GaN power and drive with control, sensing, and protection to enable faster charging, higher power density, greater energy savings and system cost reduction. New ‘Gen-3 Fast’ GeneSiC MOSFETs have up to 50% improved performance vs. other SiC devices. Summit exhibition attendees can explore the latest in EV-optimized GaNFast and GeneSiC products and complete EV system hardware solutions and learn how to accelerate their leading-edge projects.

NVTS shares lost 11 cents, or 2.7%, to $4.02.

]]>
<![CDATA[Economic Calendar]]>Thu, 25 Apr 2024 05:27:05 ESThttps://www.baystreet.ca/articles/econ_calendar.aspx?id=18125April 2024
 

DATE

STATISTIC FOR CURRENT MONTH PREVIOUS MONTH
Monday, April 1, 2024 Markit Canada Manufacturing PMI 9:30 a.m. Mar The PMI rose to 49.8 in March from 49.7 in February. The S&P Global Canada Manufacturing PMI rose to 49.7 in February of 2024 from 48.3 in the previous month.
Thursday, April 4, 2024 Canadian International Merchandise Trade: 8:30am Feb Exports increased 5.8%, while imports rose 4.6%. As a result, Canada's merchandise trade surplus with the world widened from $608 million in January to $1.4 billion in February. In January, Canada's merchandise imports decreased 3.8%, while exports fell 1.7%. As a result, Canada's merchandise trade balance changed position for a second consecutive month, moving from a deficit of $863 million in December to a surplus of $496 million in January.
Friday, April 5, 2024 Labour Force Survey: 8:30am Mar Employment was little changed in March (-2,200; -0.0%). The unemployment rate rose 0.3 percentage points to 6.1% in March Employment rose by 41,000 in February. The unemployment rate increased 0.1 percentage points to 5.8%, offsetting a decline in January.
Friday, April 5, 2024 IVEY Purchasing Managers Index: 10:00am Mar The index jumped to 57.5 in March from 53.9 in February, but was a down from March 2023's reading of 58.2. The index skidded to 53.9 in February from 56.5 in January but rose from February 2023's reading of 51.6.
Wednesday, April 10, 2024 BoC Interest Rate Decision: 10:00am Apr The Bank of Canada today held its target for the overnight rate at 5%, with the Bank Rate at 5.25% and the deposit rate at 5%. The Bank is continuing its policy of quantitative tightening. The Bank of Canada today held its target for the overnight rate at 5%, with the Bank Rate at 5¼% and the deposit rate at 5%. The Bank is continuing its policy of quantitative tightening.
Wednesday, April 10, 2024 Building Permits: 8:30am Feb The total monthly value of building permits in Canada increased 9.3% from January to $11.8 billion in February. The total monthly value of building permits in Canada increased 13.5% from December to $10.8 billion in January.
Monday, April 15, 2024 Wholesale Trade: 8:30am Feb Wholesale sales (excluding petroleum, petroleum products, and other hydrocarbons and excluding oilseed and grain) were essentially unchanged (+0.0%), at $82.2 billion in February. Wholesale sales (excluding petroleum, petroleum products, and other hydrocarbons and excluding oilseed and grain) grew 0.1% to $82.4 billion in January.
Monday, April 15, 2024 New Motor Vehicle Sales: 7:30am Feb Statistics Canada said motor vehicle sales zoomed to 137,690 in March, from 116,870 in the prior-year month. New motor vehicle sales registered at 116,870, compared to 128,830 in the same month the year before.
Monday, April 15, 2024 CREAstats - MLS Sales: 8:30am Mar National home sales edged up 0.5% month-over-month in March. Actual (not seasonally adjusted) monthly activity came in 1.7% above March 2023. Canadian home prices as measured by the seasonally adjusted Aggregate Composite MLS® Home Price Index (HPI) were flat on a month-over-month basis in February 2024, ending a streak of five declines that began last fall.
Monday, April 15, 2024 Monthly Survey of Manufacturing: 8:30am Feb Manufacturing sales increased 0.7% in February, led by the petroleum and coal product subsector as well as the electrical equipment, appliance and component subsector. Manufacturing sales rose 0.2% in January, mainly on higher sales of motor vehicles and chemical products.
Tuesday, April 16, 2024 Consumer Price Index: 8:30am Mar The Consumer Price Index (CPI) rose 2.9% on a year-over-year basis in March, up from a 2.8% gain in February. On a seasonally adjusted monthly basis, the CPI rose 0.3% in March. The Consumer Price Index (CPI) rose 2.8% on a year-over-year basis in February, down from a 2.9% gain in January. On a seasonally adjusted monthly basis, the CPI rose 0.1% in February.
Tuesday, April 16, 2024 Housing Starts: 8:15am Mar Housing starts totaled 242,200 in March, compared to 260,000 in the prior-year month. Housing starts totaled 253,000 in February, compared to 223,200 in the same month last year.
Wednesday, April 17, 2024 Canada's International Transactions in Securities: 8:30am Feb Canadian investors acquired $24.2 billion of foreign securities in February, led by an all-time high investment in foreign bonds. Meanwhile, foreign investors reduced their exposure to Canadian securities by $8.8 billion, led by a record divestment in government short-term debt securities. Foreign investment in Canadian securities amounted to $8.9 billion in January, led by acquisitions of government debt securities. Meanwhile, Canadian investors reduced their holdings of foreign securities by $7.6 billion, led by sales of equity securities.
Monday, April 22, 2024 Raw Materials Price Index: 8:30am Mar The Raw Materials Price Index rose 4.7% from February to March and was up 0.8% year over year in March. The index increased 2.1% month over month in February 2024 and decreased 4.7% year over year.
Monday, April 22, 2024 Industrial Product Price Index: 8:30am Mar The Industrial Product Price Index increased 0.8% month over month in March and fell 0.5% on a yearly basis The index rose 0.7% on a monthly basis in February and fell 1.7% relative to February 2023.
Wednesday, April 24, 2024 Retail Trade: 8:30am Feb Retail sales decreased 0.1% to $66.7 billion in February Retail sales decreased 0.3% to $67.0 billion in January. Sales were down in three of nine subsectors and were led by decreases at motor vehicle and parts dealers
Wednesday, April 24, 2024 New Housing Price Index: 8:30am Mar The index was flat on a monthly basis during March, compared to a gain of 0.1% the month before. The index sank 0.4% last month on an annual basis, identical to March last year. The national index edged up 0.1% month over month in February.
Thursday, April 25, 2024 Payroll Employment, Earnings and Hours: 8:30am Feb The number of employees receiving pay and benefits from their employer—measured as "payroll employment" in the Survey of Employment, Payrolls and Hours—decreased by 17,700 (-0.1%) in February, following an increase of 35,700 (+0.2%) in January. On a year-over-year basis, payroll employment was up by 154,700 (+0.9%) in February. The number of employees receiving pay and benefits from their employer—measured as "payroll employment" in the Survey of Employment, Payrolls and Hours—increased by 39,800 (+0.2%) in January.
Tuesday, April 30, 2024 GDP: 8:30am Feb --- Real gross domestic product rose 0.6% in January as both services-producing and goods-producing industries posted gains
]]>
<![CDATA[Canada’s Retail Sales Stalled In First Quarter ]]>Thu, 25 Apr 2024 07:24:00 ESThttps://www.baystreet.ca/articles/economiccommentary.aspx?id=4068Canada’s Retail Sales Stalled In First Quarter


Canada’s retail sales stagnated to start the year as consumers pulled back on discretionary spending.

According to data from Statistics Canada, retail sales across the country were flat in this year’s first quarter, marking the weakest pace of consumer spending since the second quarter of 2023.

The drop in retail sales was led by spending at gas stations as the cost to fill a vehicle’s tank rose between January and March. On the flipside, car sales rose during Q1.

However, excluding gas stations and automotive dealers, core retail sales were unchanged in the period as consumers cutback discretionary spending on clothing and other items.

Regionally, sales were down in seven Canadian provinces, with the largest declines seen in Alberta, Ontario, and Quebec.

The weak retail sales bolster the case that the economy is slowing and could embolden the Bank of Canada to begin cutting interest rates at its next policy meeting in June.

]]>
<![CDATA[Rally Halts, Japan Leads Losses ]]>Thu, 25 Apr 2024 06:47:00 ESThttps://www.baystreet.ca/articles/foreignmarketwrap.aspx?id=4415Thursday, April 25, 2024

Rally Halts, Japan Leads Losses


Asia-Pacific markets took a breather after two straight days of rallies, mirroring moves on Wall Street ahead of first-quarter gross domestic product figures from the U.S. due Thursday.

The Nikkei 225 Index erased gains from the day before, losing 831.6 points, or 2.2%, to 37,628.48. The yen was still trading firmly beyond the 155 mark against the greenback, at 155.63.

The Bank of Japan kicked off its monetary policy meeting Thursday as investors continue to monitor for action against yen weakness. The yen slid past the 155 mark against the U.S. dollar on Wednesday, hitting a fresh 34-year low.

In Hong Kong, the Hang Seng index advanced 83.27 points, or 0.5%, to 17,284.54.

Investors will also assess South Korea’s advance first-quarter GDP growth of 3.4% year on year, the highest quarterly growth since the fourth quarter of 2021.

In other markets

In Shanghai, the CSI 300 eked higher 8.66 points, or 0.3%, to 3,530.28.

In Korea, the Kospi retreated 47.13 points, or 1.8%, to 2,628.62.

In Singapore, the Straits Times Index sank 5.38 points, or 0.2%, to 3,287.75.

In Taiwan, the Taiex index tumbled 274.32 points, or 1.4%, to 19,857.42.

Markets in Australia and New Zealand were closed in honour of ANZAC Day

]]>
<![CDATA[Norway’s Sovereign Wealth Fund Posts $110 Billion Profit ]]>Thu, 18 Apr 2024 09:12:00 ESThttps://www.baystreet.ca/articles/globalmarkets.aspx?id=3524Norway’s sovereign wealth fund, the largest of its kind in the world, has reported a first-quarter profit of $109.9 billion U.S. due largely to its investments in technology stocks.

The “Norway Government Pension Fund Global,” as it is officially known, was valued at $1.61 trillion U.S. at the end of March this year.

The return on the fund’s stock investments in Q1 came in at 9.1%. Much of that gain came from investments in meg-cap tech stocks such as Amazon (AMZN) and Nvidia (NVDA).

One of the world’s largest investors, Norway’s sovereign wealth fund was established in the 1990s to invest surplus revenues from the country’s oil and gas sector.

To date, the fund has put money into more than 8,800 companies across 70 countries.

However, while the return on its equity investments was strong, Norway’s sovereign wealth fund saw weak results from its real estate holdings during the January through March quarter.

]]>
<![CDATA[TSXV New Listings]]>Mon, 09 Jan 2023 12:18:00 ESThttps://www.baystreet.ca/articles/ipo_tsx.aspx?id=10023 Company Name Ticker Date Hopefield Ventures Two Inc. HVII.P 09-01-2023 Palisades Goldcorp Ltd. PALI 06-02-2023 Haviland Enviro Corp. HEC.P 07-02-2023 Mandala Capital Inc. MAN.P 08-02-2023 Scaling Capital 1 Corp. SKAL.P 10-02-2023 Can-Gow Capital Inc. GOWC.P 16-02-2023 Goodbridge Capital Corp. GODB.P 22-02-2023 Fraser Mackenzie Accelerator Corp. FMAC.P 22-02-2023 NorthStar Gaming Holdings Inc. BET 08-03-2023 Eureka Capital Corp. EBCD.P 09-03-2023 Totec Resources Ltd. TOTC 10-03-2023 Sage Potash Corp. SAGE 20-03-2023 Lumine Group Inc. LMN 24-03-2023 NL2 Capital Inc. NLII.P 28-03-2023 SP Strategic Acquisition Corp. SPSA.P 31-03-2023 DAVIDsTEA Inc. DTEA 03-04-2023 5D Acquisition Corp. FIVD.P 14-04-2023 SouthGobi Resources Ltd SGQ 17-04-2023 Snowline Gold Corp. SGD 04-05-2023 ALDD Ventures Corp. ALDD.P 05-05-2023 Ankh II Capital Inc. AUNK.P 12-05-2023 Argo Opportunity Corp. AROC.P 18-05-2023 Raging Rhino Capital Corp. RRCC.P 24-05-2023 G2M Cap Corp. GTM.P 25-05-2023 CNJ Capital Investments Inc. CNJ.P 21-06-2023 Kalma Capital Corp. KALM.P 23-06-2023 MDK Acquisition Inc. MDK.P 28-06-2023 Thunderbird Minerals Corp. BIRD 29-06-2023 Upstart Investments Inc. UPT.P 29-06-2023 Midwest Energy Emissions Corp MEEC 10-07-2023 Logan Energy Corp. LGN 18-07-2023 Cascadia Minerals Ltd. CAM 19-07-2023 Constellation Capital Corp. CNST.P 20-07-2023 Blue Sky Global Energy Corp. BGE 20-07-2023 Onyx Gold Corp. ONYX 24-07-2023 Space Kingdom Digital Capital Corp. YSK.P 27-07-2023 Pardus Ventures Inc. PDVN.P 27-07-2023 Prestwick Capital Corporation Limited PWIK.P 31-07-2023 Odessa Capital Ltd. ALFA.P 03-08-2023 EVP Capital Inc. EVP.P 04-08-2023 Relevant Gold Corp. RGC 09-08-2023 Pulsar Helium Inc. PLSR 15-08-2023 SRQ Resources Inc. SRQ 16-08-2023 Bunker Hill Mining Corp. BNKR 11-09-2023 Tactical Resources Corp. RARE 31-08-2023 LNG Energy Group Corp. LNGE 12-09-2023 V Ten Capital Corp. VTEN.P 27-09-2023 Sendero Resources Corp. SEND 04-10-2023 Medicus Pharma Ltd. MDCX 11-10-2023 The Fresh Factory B.C. Ltd. FRSH 05-10-2023 Cosa Resources Corp. COSA 18-10-2023 Sucro Limited SUG 30-10-2023 Li-FT Power Ltd. LIFT 01-11-2023 Jo-Jo Capital Canada Ltd. JOJO.P 16-11-2023 Premier American Uranium Inc. PUR 01-12-2023 Rockmount Capital Corporation RSC.P 14-12-2023 Cubicfarm Systems Corporation CUB 19-12-2023 Dryden Gold Corp. DRY 29-12-2023 Mawson Gold Limited MAW 04-01-2024 Artrari One Capital Corp. AOCC.P 05-01-2024 Euromax Resources Ltd. EOX 09-01-2024 Oa Capital Corp. OACP 09-01-2024 Power One Resources Corp. PWRD 18-01-2024 Zodiac Gold Inc. ZAU 29-01-2024 Amaya Big Sky Capital Corp. AMYA.P 30-01-2024 Coco Pool Corp. CCPC.P 08-02-2024 Goldgroup Mining Inc. GGA 20-02-2024 Navion Capital II Inc. NVN.P 29-02-2024 Atha Energy Corp. SASK 04-03-2024 Sitka Gold Corp. SIG 05-03-2024 Kubera Gold Corp. KBRA 13-03-2024 Coniagas Battery Metals Inc. cOS 18-03-2024 Valleyview Resources Ltd. VVR 28-03-2024]]><![CDATA[TSX Moves Doggedly into Green ]]>Thu, 25 Apr 2024 04:39:00 ESThttps://www.baystreet.ca/articles/marketupdates.aspx?id=13100Thursday, April 25, 2024

16:39 PM EST
TSX Moves Doggedly into Green

New Gold, MAG in Forefront



Equities in Canada’s largest centre survived a volatile day Thursday, coming out on the positive side, on the strength of resource stocks.

The TSX Composite gained 11.66 points to wrap up Thursday at 21,885.38.

The Canadian dollar recovered 0.25 cents at 73.23 cents U.S.

Gold led the sectors making headway Thursday, with New Gold acquiring 12 cents, or 5.1%, to $2.48, while OceanaGold hiked a dime, or 3.3%, to $3.13.

In materials, Teck Resources climbed $5.42, or 8.7%, to $67.65, while MAG Silver popped $1.15, or 7%, to $17.70.

In energy, Secure Energy rumbled 49 cents, or 4.4%, to $11.56, while Advantage Oil jumped 36 cents, or 3.5%, to $10.73.

Sylogist led the tech sector downward, losing 36 cents, or 3.9%, to $8.88, while BlackBerry ditched 15 cents, or 3.8%, to $3.80.

Real-estate stocks also plunged, with StorageVault giving back 31 cents, or 6.1%, to $4.76, while FirstService gave up $4.91, or 2.3%, to $207.30.

In health-care, Tilray lost 11 cents, or 4.4%, to $2.41, while Chartwell Retirement Residence units parted with three cents to $12.46.

Statistics Canada reported the number of employees receiving pay and benefits from their employer decreased by 17,700 (-0.1%) in February, following an increase of 35,700 (+0.2%) in January. On a year-over-year basis, payroll employment was up by 154,700 (+0.9%) in February.

ON BAYSTREET

The TSX Venture Exchange recovered 3.68 points to end the session at 578.33.

Eight of the 12 TSX subgroups were lower midday, with information technology down 1.8%, health-care pointed downward 0.9%, and real-estate off 0.8%

The three gainers were gold, prospering 4%, materials, stronger by 2.2%, and energy, edging up 0.7%.

ON WALLSTREET

Stocks tumbled Thursday after the latest U.S. economic data showed a sharp slowdown in growth and pointed to persistent inflation.

The Dow Jones Industrials dropped 375.19 points, or 1%, at Thursday’s close to 38,085.73, weighed down by steep declines in Caterpillar and IBM

The S&P 500 index flopped 23.21 points to 5,048.42.

The NASDAQ Composite fell 100.99 points to 15,611.76.

Meta plunged 10.5% after the social media giant issued light revenue guidance for the second quarter. That would be the stock’s biggest one-day decline since October 2022. International Business Machines also fell 8.3% after missing consensus estimates for first-quarter revenue.

Meta’s report raises concern ahead of other big tech releases. Microsoft and Alphabet are slated to post earnings after the close Thursday.
U.S. gross domestic product expanded 1.6% in the first quarter, the Bureau of Economic Analysis said. Economists polled by Dow Jones forecast GDP growth would come in at 2.4%.

Following the GDP print, traders moved down expectations for an easing of Federal Reserve monetary policy. Traders now forecast just one interest rate cut this year.

The lackluster GDP added further pressure to an already-tense market contending with concerns over a pullback in growth among technology earnings.

Prices for the 10-year Treasury slumped yields to 4.70% from Wednesday’s 4.64%. Treasury prices and yields move in opposite directions.

Oil prices climbed 95 cents to $83.76 U.S. a barrel.

Gold prices revived $5.90 to $2,344.30 U.S. an ounce.




]]>
<![CDATA[Stocks in Play: Alset Capital Inc.]]>Thu, 25 Apr 2024 11:26:40 ESThttps://www.baystreet.ca/articles/stocksinplay.aspx?id=41937Thursday, April 25, 2024

11:26 AM EST - Alset Capital Inc. : Announced that its 49% owned investee company, Cedarcross International Technologies Inc., has entered into a two-year AI Computing leasing agreement, with an arm's length counterparty. The Agreement is expected to generate approximately CAD$5.5 million in total revenue, with aggregate gross margin of approximately CAD$4.4 million over the contract's duration. Under the terms of the Agreement, Cedarcross Technologies will provide approximately 700,000 compute hours annually, totaling 1.4 million AI compute hours over the contract's duration. This agreement, with an esteemed arm's length third-party enterprise client, underscores Cedarcross Technologies growing influence and capabilities in the realm of AI infrastructure. The Agreement outlines a structured monthly payment plan, with Cedarcross Technologies expecting to receive approximately CAD$223k monthly. Alset Capital Inc. (V.KSUM) shares were off 2 cents at 0.36.

]]>
<![CDATA[The Race to Build AI Infrastructure: Who Will Power the Next Tech Revolution?]]>Thu, 25 Apr 2024 11:25:42 ESThttps://www.baystreet.ca/articles/stockstowatch.aspx?id=17783Thursday, April 25, 2024

The Race to Build AI Infrastructure: Who Will Power the Next Tech Revolution?


VANCOUVER – USA News Group – The economic impact of the AI revolution is growing at a hyperbolic rate, with analysts at PWC projecting AI’s potential contribution to the global economy to hit US$15.7 trillion by 2030. Behind the scenes powering this shift are many players building out the infrastructure to provide the supercomputing power necessary to fulfill AI’s soaring demand, which alone is projected to consume enough energy to power a small country. While analysts are projecting the Computing Power Market to surpass US$81.3 billion by 2032, the biggest logistical threat to the AI wave are shortages and rising prices of GPUs, the chips that are used to propel generative AI programs. The current leader in providing GPUs is chipmaking giant NVIDIA Corporation (NASDAQ: NVDA), however there are other important players moving their pieces into place to also make an impact, including Alset Capital Inc. (TSXV: KSUM), VERSES AI Inc. (NEO: VERS) (OTCQB: VRSSF), Super Micro Computer Inc. (NASDAQ: SMCI), and SAP SE (NYSE: SAP).

One of the most sought after GPUs in the AI arms race is the Hopper H100 AI GPU from NVIDIA Corporation (NASDAQ: NVDA), which currently has a 2-3 month wait time to deliver orders. Meanwhile speculators are buying up the H100s and driving the price beyond $40,000 per unit, creating advantages in the market for entities with contracts in place to buy these GPUs faster, and cheaper than competitors.

This is precisely the advantage that Alset Capital Inc. (TSXV: KSUM) has captured through its 49%-owned investee company Cedarcross International Technologies Inc., which offers access to the world’s fastest AI servers, powered by NVIDIA’s H100 HGX Servers. Recently, Alset announced that Cedarcross has just entered into a two-year AI Computing leasing agreement, which is expected to generate approximately C$5.5 million in revenue, and comes with a gross margin of approximately 80% over the contract’s duration.

Under the agreement, Cedarcross is set to supply ~700,000 compute hours each year, amounting to approximately 1.4 million AI compute hours over the term of the contract. The deal, struck with a respected, independent third-party enterprise client highlights Cedarcross's expanding presence and expertise in the AI infrastructure sector, and its increasing value for Alset. This also follows up on other distribution agreements from earlier in the month, including one that will bring in C$2.3 million in gross revenue, and another that comes with a supply agreement that permits Cedarcross to purchase Nvidia high-performance computing servers from Super Micro Computer Inc. (NASDAQ: SMCI), through its partnership with Earthmade Computing.

"We are very enthusiastic about Cedarcross's strategic collaboration with Earthmade Computing to purchase Nvidia HPC servers directly from Super Micro Computer, Inc.," said Morgan Good, CEO of Alset regarding the supply agreement. "This Agreement not only ensures the seamless procurement of vital AI computing hardware but also solidifies Cedarcross's competitive positioning in the industry."

With these two recent announcements, Cedarcross has solidified agreements poised to generate a cumulative expected gross revenue of C$7.8M year to date. These agreements span across its compute leasing business and its high-performance computing distribution vertical, marking significant milestones in Cedarcross's growth trajectory, and delivering early solid returns for Alset’s investments in the process.

Setting up intelligent software systems for potential clients, VERSES AI Inc. (NEO: VERS) (OTCQB: VRSSF) has announced at least six Beta engagements of its flagship GeniusTM platform. These engagements include a series of potentially significant clients, an agreement with an yet-to-be-named national US pharmacy retailer and a partnership involving potential smart city projects in Abu Dhabi.

“For an early-stage company we have so much going on, especially in the last few months,” said Gabriel René, founder and CEO of VERSES. Additionally, VERSES has received over 3,700 sign ups for the limited private preview of its Genius™ Public Beta program. To date, the company has grown to around 100 employees across 60 remote locations, and has raised $65 million.

VERSES has also made a bold claim that the machine-learning methods behind ChatGPT and the rest of AI's advances for the past 20 years will never get the industry to artificial general intelligence (AGI)—a human level of AI that can reason and learn in new ways. The company says it will release the public beta version of GeniusTM later this summer.

As part of its mission to help every business run as an intelligent, sustainable enterprise, enterprise application software provider SAP SE (NYSE: SAP) recently signed a partnership expansion with NVIDIA Corporation (NASDAQ: NVDA) to benefit SAP’s portfolio of cloud solutions and applications. As per the deal, the two companies are collaborating to build and deliver SAP Business AI to include scalable, business-specific generative AI capabilities across SAP’s offerings, providing instant access to a broad range of large language models (LLMs). Together, SAP and NVIDIA plan to make the new integrated capabilities available before the end of the year, as SAP will use NVIDIA’s generative AI foundry service to fine-tune the LLMs with new NVIDIA NIMTM microservices.

"Strategic technology partnerships, like the one between SAP and NVIDIA, are at the core of our strategy to invest in technology that maximizes the potential and opportunity of AI for business," said Christian Klein, CEO and Member of the Executive Board of SAP SE. "NVIDIA's expertise in delivering AI capabilities at scale will help SAP accelerate the pace of transformation and better serve our customers in the cloud."

Leading innovator in enterprise, cloud, AI, and 5G Telco/Edge IT infrastructure Super Micro Computer Inc. (NASDAQ: SMCI) recently announced its upcoming X14 server portfolio that’s set to have future support for the Intel Xeon 6 processor. The new system will combine Supermicro’s Building Block Architecture, rack plug-and-play and liquid cooling solutions, while also including the Intel Xeon 6 processor’s help to deliver optimized solutions for any workload at any scale, with superior performance and efficiency.

"Supermicro leads the industry in the design and delivery of a wide range of application optimized solutions, and our new X14 systems with the upcoming Intel Xeon 6 processors will further expand our already broad range of offerings," said Charles Liang, president and CEO of Supermicro. "With our production capacity of 5,000 racks per month globally, including 1,350 liquid-cooled 100 kW racks, and lead time as short as 2 weeks, Supermicro is unmatched in its ability to design, build, validate, and deliver fully customized, workload-optimized rack-scale solutions to our customers, including the most advanced AI hardware available today."



CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873



DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Alset Capital Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Alset Capital Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Alset Capital Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Alset Capital Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

]]>
<![CDATA[USD / CAD - Canadian Dollar firming ahead of US GDP]]>Thu, 25 Apr 2024 12:01:58 ESThttps://www.baystreet.ca/articles/forex_trader.aspx?id=96972- US Q1 GDP expected to rise 2.5%.

- German data underpinning EURUSD

- USD trades defensively and slips against the majors.

USDCAD: open 1.3677, overnight range 1.3670-1.3708 close 1.3702, WTI $82.73, Gold, $2324.98

The Canadian dollar continues to seesaw inside the well-defined USDCAD range of 1.3650-1.3740 that has contained price action since last Friday.

Today’s focus is squarely on the US Q1 GDP report, which is expected to show that the American economy grew by 2.5%, adding further support to the “soft-landing” argument. The soft-landing view is further reinforced by the Atlanta Fed's EconomyNow forecast of 2.7% for GDP.

The sustained resilience of the U.S. economy is evident in the face of ongoing Federal Reserve rate hikes that began in March 2022. Financial conditions have adapted to higher market yields without significant tightening across multiple measures. Credit spreads remain tight, and the S&P 500 has only slightly receded from its peak, indicating continued investor confidence. Moreover, the dollar's strength boosts consumer purchasing power, mitigating the impact of higher import costs.

Global equity markets are trading mixed to lower. In Asia, Australian and New Zealand markets were closed for ANZAC Day celebrations. Japan’s Nikkei 225 index dropped 2.16%. European equity indexes are slumping except for the UK’s FTSE 100 index, which has risen 0.63%. Wall Street is poised to open with losses as S&P 500 futures have dropped 0.70%.

EURUSD traded firmer in a 1.0694-1.0730 range with prices supported by the mix of strong German Ifo data yesterday and today’s better-than-expected Consumer Sentiment data (actual -24.2, previously -27.3). EURUSD resistance in the 1.0750-60 area is reinforced by $1.6 billion of option strikes rolling off at 10 am.

GBPUSD is bid in a 1.2444-1.2523 range after comments by Bank of England Chief Economist Hu Pill raised fears that the BoE may not be easing as soon, or as fast as other policymakers had indicated.

USDJPY is in demand and climbed from 155.20 to 155.75 range overnight, BoJ and Finance Ministry officials continue with their verbal intervention but traders say “action speaks louder than words.” The US 10-year Treasury yield is at 4.642%, adding further support to prices.

AUDUSD traded in a 0.6482-0.6531 range in quiet trading with prices tracking broad US dollar sentiment.

US data includes weekly jobless claims, Pending home sales, Wholesale inventories, and PCE




]]>
<![CDATA[Citigroup Vaults On Beating Quarterly Projections]]>Thu, 12 Oct 2017 10:07:02 ESThttp://www.baystreet.ca/articles.aspx?id=38460Earnings per Share came in for the quarter at $1.42, as opposed to $1.32 expected by experts. Revenue was $18.173 billion versus $17.896 billion expected. Fixed income trading: $2.877 billion versus a projected $2.84 billion

Said CEO Michael Corbat, "We had revenue increases in many of the products we have been investing in, tightly managed our expenses, and again saw loan growth in both our consumer and institutional businesses.”

Citi reported a 3% year-over-year increase in global consumer banking revenue. In North America, retail banking revenue rose 12%, excluding mortgages. Citi cited "continued growth in loans and assets under management," as well as higher interest rates.

The bank's international consumer business saw an 8% revenue increase, driven by higher loans and deposit volumes growth.

Citi's end-of-period loans, meanwhile, rose 2% to $653 billion, while deposits increased by 3% to $964 billion.

Shares of Citigroup have risen 26% this year, easily outperforming the broader market. The S&P 500 has gained 14% in 2017.

Citigroup's stock has also outperformed those of other big banks. Shares of JPMorgan Chase and Bank of America are up 11.9% and 16.9%,, respectively.

Folks who follow macroeconomic developments are also aware that Citigroup could benefit from tighter monetary policy in the near future. The U.S. Federal Reserve signaled a December rate hike in the summary of its Sept. 20 meeting.
Shares in C opened Thursday took on 31 cents to $75.25. ]]>
<![CDATA[Enterprise Group’s Hart Oilfield Rentals: Custom, Cost-Effective Infrastructure]]>Thu, 12 Oct 2017 09:51:46 ESThttp://www.baystreet.ca/articles.aspx?id=38459


Simply, if you are building a mining or oil business Hart rents customized equipment for project sites, drilling & completions and facilities that require mobile infrastructure.

It makes zero sense to expend valuable capital to purchase generators, offices, WC’s etc. As well, each project is different so flexibility, customization and ease of transport is key.



“Our large competitive advantage is the ability to what we refer to as ‘combo technology,” states Joel Bardwell, Senior Manager at Hart. “Whether on a skid or one of our proprietary portable trailers, we can deliver not only the equipment required, but customize it to be the most cost effective. Customers appreciate the approach and with our ongoing R&D and patent/patent pending profile, both served us well during the downturn and positions us well for the rapidly increasing business, both from previous and new clients.”

Hart currently has 6 locations that are strategically located throughout west central and northern Alberta and northeastern British Columbia. These 6 locations have allowed Hart to establish 6 complimentary “service circles” that slightly overlap and allow Hart to deliver oilfield site set-up services and equipment rentals efficiently to its customers as well as respond quickly to requests for service or repairs to its equipment when required.

Early on, Hart realized that the uniqueness of its approach warranted patent filings for equipment as well as industrial designs. With approximately 25 equally divided between Canada and the US, the practice both cements Hart’s reputation as an innovator as well as protect the Company and Enterprise shareholders from interlopers.

There are always interlopers.



It should also be noted that Hart does not sell the custom equipment. Hart is constantly developing equipment to add to its robust and state of the art rental pool: And all with
safety the primary consideration.

Just as with all the Enterprise Group’s subsidiaries, attention to detail is a given. Reactive and proactive to customer needs is what cuts it out of what is already a small herd. Whether resource, municipal needs, pipelines or any other infrastructure pursuit, that word - infrastructure - should be reflected to a greater or lesser degree in every portfolio. US peers are hitting new highs and others, such as Enterprise’s share price is being wrongly assaulted by a volatile oil price.

The bottom line is that over the years Enterprise has made savvy, money making purchases and sales. TC Backhoe sold in 2016 for approximately C$20 million. The Company was purchased in 2007 for C$12 million and under the Enterprise umbrella generated $150 million. The sale was done during the recent downturn, but had been planned previously and drastically lowered and improved the Company’s financials.

Having successfully steered through a blistering downturn, which seems to have unfairly punish a stock that has a breakup of C$0.85 but is trading at C$0.30, it seems a good addition to a junior portfolio.

Investors will also note that as the Company is traded on the TSX that adds to a list of bonafides to Enterprise that investors would be wise to take stock.



Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated ten thousand dollars for its efforts in distributing the TSX:E profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[WADA Lifts CBD Ban for Professional Athletes and their Doctors]]>Thu, 12 Oct 2017 08:02:09 ESThttp://www.baystreet.ca/articles.aspx?id=38458
The World Anti-Doping Agency (WADA) just removed hemp-derived cannabidiol (CBD) from its 2018 List of Prohibited Substances, freeing up athletes in the largest international athletic associations in the world like the IOC and FIFA as well as major sports leagues like UFC, NCAA, NFL, NBA, NHL, MLB, and many more to use CBD-infused products as to treat pain and inflammation based disorders.

As WADA is a global governing body, now athletes around the world can use CBD to treat pain, inflammation and injuries, without the risk of league suspension or a loss of sponsors. Professional athletes around the world can now use Phivida’s CBD infused functional foods and natural health brands, free from WADA restrictions, for the first time in the history of competitive sports.

Cannabinoids have just got mainstream, starting with the major leagues. But it’s investors, and CBD-infused infused functional foods and natural health products brands that stand to benefit the most.

According to Allied Research, the global anti-Inflammatory therapeutics market is projected to top $106 Billion USD by 2020, dominated by OTC drugs like Ibuprofen ($14.2 billion USD by 2022). The US opiate drug as an additional $17.7 billion USD by 2021 dominated by Oxycontin, Percocet and Vicodin. Both the NSAIDs and opiate markets are dominated by pain and inflammation pharmaceutical mogul Bayer (BAYN.DE), with a market capital of over $96 billion.

Cannabidiol is widely studied as a powerful anti-inflammatory and was even part of a US Department of Health patent application for anti-oxidant and neuroprotectant properties.

RISING DEMAND FOR CBD-INFUSED PRODUCTS

Timing the market is vital for maximizing investment returns. There is no better example of fortunate timing than WADA’s announcement coinciding with the launch of Phivida Holdings Inc.’s CBD-infused functional foods and natural health products, and the filing of prospectus for an initial public offering and an application to list its class A shares on the Canadian Securities Exchange (CSE).

As a premiere CBD brand, Phivida is perfectly positioned to capture a leadership market share in this emerging global natural health products market. The Phivida IPO offers investors with exposure to three major growth trends within a global health and wellness $1 Trillion USD in 2017.

Bloomberg predicts US cannabinoid products as a $50 billion USD market by 2020. Within the cannabinoids market, Phivida has created its own unique products category – functional CBD edibles.

High Times magazine produces a top ten edibles list and this year six of them were cannabinoid infused beverages. Phivida specializes in the CBD beverages avoiding a saturated confectionary soft drinks market with functional CBD iced teas, CBD protein shakes and CBD vitamin juices.

Health care practitioners, and now sports medicine professionals, and major nutraceutical distributors cite the paradigm shift from chemical based pharmaceuticals to phytonutraceuticals.

Supplements as a whole market is exploding, having gone from a $37 billion US estimate in 2015, to an expectation of $220 billion globally by 2022.

Nutrition Business Journal cites the two fastest growing categories as; meal replacements (14.8%) and sports nutrition (11.6%), two flagship CBD product lines at Phivida – both infused with a high dose of cannabidiol. Phivida’s nanoencapsulation technology loads CBD into a protective, hydrophilic, liposomal membrane that bonds better with cells. The result is a faster acting longer lasting absorption rates, with up to 400% more bioavailability and a timed release for enhanced duration in the bloodstream, and solubility.

Functional foods have surpassed traditional food topping a $100 billion USD back in 2015. The functional food industry is in the process of a massive consolidation as over $10 billion USD of new M&A deals were completed in 2016 alone.

Major food companies are acquiring new organic and functional food brands at a staggering rate, lead by multi-national conglomerates such as Hains Celestial (NASDAQ: HAIN), PepsiCo (NYSE:PEP) and General Mills (NYSE:GIS).

It’s no wonder that major retailers in both the grocery sector, and the nutritional supplements space are champing at the bit to grow their selection of products for consumers.

WADA’s prohibition lift may be the catalyst needed for supplement giant GNC Holdings Inc. (NYSE:GNC) to get its year back on track. Having fallen from over $20 to just over $8 within the year, the ability to introduce new lines of nutritional supplements with pain relieving qualities could be a shot in the arm for GNC.

Whereas major grocery and pharmacy chains, such as Canadian retail giant Loblaw Companies Inc. (TSX:L)(OTC:LBLCF), which owns the well-established Shoppers Drug Mart chain. Unlike GNC, which to-date has been reluctant to carry CBD products in-store, Shoppers Drug Mart has been very open about its willingness to carry CBD and marijuana-related products on its shelves.

It’s still to be determined when and if that same level of acceptance will be seen on the US side of the border. GNC currently doesn’t carry any CBD-infused products, selling only hemp proteins as a remotely close cousin. Nor is CVS Health Corporation (NYSE:CVS), yet.

Online mega-retailer Amazon.com Inc. (NASDAQ:AMZN) is already selling CBD products. On track to hit the very first $1 trillion valuation, Amazon is ahead of the curve on the blossoming CBD sector.

Whole Foods CEO John Mackey stated he would support cannabinoid products sold in Wholefoods “if only the plant was legal to use and the local community approved.”

Not only is CBD-Hemp Oil extract legal under the Farm Bill, but WADA’s new rules has the potential for a massive demand from professional athletes, sports medicine practitioners and alternative health care practitioners and the everyday active health conscious consumer. It looks like John might get his wish.

Plant-based supplements like CBD are no longer limited to the estimated 17,500 licensed alternative health care practitioners, as majority of supplements are now sold through big box FCMD (food, club, mass and drug) retail locations.

Walgreens, CVS and Walmart combined for a total of 27,087 on-site pharmacists at 15,208 stores across the United States. With Amazon’s acquisition of Wholefoods earlier this year, it’s clear that the majors are looking to capitalize on the health-conscious consumer.

Now it’s a matter of CBD’s true market infiltration to take hold, and for producers to begin stocking only the best CBD infused FFNHP formulations.

Primed and ready to supply these retailers with timely product, Phivida boasts an entire line of CBD functional foods and natural health products, doctor formulated for enhanced athletic performance and everyday preventative health for active families.

INDUSTRY AND ORGANIC ADVANTAGE

Totally legal, and boasting a laundry list of health benefits, cannabidiol (CBD) is making waves through the food and beverage industry in the form of several new products.

So it’s no wonder that any new producer of CBD products will want to seek out the expertise of those already familiar with the food and beverage industry.

Assembling an impressive array of talent, Phivida’s management team is built to master not only its formulation, but also its branding and retail distribution.

Among the names on the company’s deck are Directors Bill Ciprick and James Bailey, who each come with decades of branding and distribution experience for industry heavy-hitters, such as Proctor and Gamble Health Care, and Red Bull Canada.

But for the consumer, the most important aspect to consider beyond retail availability is that of the product’s organic, whole-plant blends and formulations.

Phivida infuses full-spectrum CBD Hemp Oil extracts into special blends of functional foods and natural health products (FFNHP). All nanoencapsulated CBD used in Phivida’s products is hemp-derived from licensed hemp farms and federally legal and eligible for sale in any retail channel.

The company’s CBD-infused functional beverages are nanoencapsulated for enhanced bioavailability, and doctor-formulated for targeted outcomes. Phivida boasts quality-, and safety-tested products that are cGMP manufactured to the highest quality assurance standards.

Phivida CBD Vitamin Drinks use certified organic and plant-based ingredients. Phivida’s CBD infusions are also vegan, gluten- and soy-free with no sugar added and contain at least 35% RDA of Vitamin B complex and Vitamin C.

Other key sports performance ingredients include premium electrolyte replacements, glutamine for muscle, bone and joint repair, resveratrol for added anti-oxidants, blended in an all-natural fruit and vegetable puree with no artificial colours or flavours added.

Former President of the BC College of Naturopaths, Dr. Brian Martin, states; “Phivida offers legal, clinical grade, CBD, third-party tested, and safe for practitioners to recommend to athletes and patients.” Marijuana is federally illegal in the United States, but hemp provides a legal option for clinicians. WADA’s new ruling now opens CBD to team physicians, physiotherapists, nutritionists and kinesiologists. “Phivida is a high-quality brand for athletes who need healthier, non-addictive treatments for pain and inflammation,” said Dr. Martin.

WADA’s now-positive stance on CBD represents a great opportunity for Phivida. Competitive athletes in high-impact sports like football, hockey and mixed martial arts are often plagued with a lifetime of debilitating physical injuries and mental health conditions.

Phivida’s CBD infusions give athletes, their trainers, and medical staff a whole-plant nutraceutical alternative to highly addictive opiate pharmaceuticals to treat chronic pain and inflammation from these injuries and afflictions.

ATHLETIC ENDORSEMENT

Earlier this year, the New York Times published a neuropathology study that found that 99% of former NFL players tested positive for Chronic Traumatic Encephalopathy (CTE). The NFL supports the NFL Players Association’s (NFLPA) study on the use of cannabinoids to treat chronic pain inflammation based disorders, like CTE, according to a Sports Illustrated article published on August 1st, 2017.

The NFLPA was coincided by the launch of the Your Mind Your Body Campaign designed to equip current and former players with the tools needed to achieve a healthy lifestyle, both physically and mentally and encourages an open dialogue on pressing health and safety issues, including CTE, and mental health.

Use of cannabinoid-based alternatives to opiates is not a new issue for the NFL. Many former players have become advocates for CBD as alternatives to narcotics, including former Baltimore Raven Eugene Monroe, Denver Bronco Jake Plummer, Chicago Bear Jim McMahon, and Ricky Williams who publicly stated a belief that “60-70% of all NFL athletes use medicinal marijuana”.

Despite the fact that both the NFLPA and NFL endorse a study of marijuana as a potential pain-management tool, the NFL currently suspends players who test positive for the drug and modified the threshold for a positive test for marijuana (i.e. THC). Finally, WADA’s new adoption of CBD as an approved substance, gives the NFL and its players hope for immediate relief, without controversy.

Phivida’s CBD-infused functional foods and natural health products are formulated with a special blend of nutraceuticals for enhanced athletic performance, and infused with a therapeutic dose of nanoencapsulated cannabidiol from hemp.

"This pain is never going away. My body is damaged," Eugene Monroe, 30, stated in a Washington Post article. "I have to manage it somehow. Managing it with pills was slowly killing me.”

With the lift on the CBD ban, WADA is finally taking sensible action on behalf of the athletes it is tasked to protect.

“Cannabidiol is no longer prohibited,” WADA said, maintaining that THC will remain as a banned substance. WADA cited the reason for the removal of cannabidiol from the banned list was because “it is not a cannabimimetic and does not mimic the effects of THC.”

WADA further clarified: “THC is still a prohibited substance.”

THC or tetrahydrocannabinol is the psychotropic chemical compound in marijuana that contributes to euphoric effects. Many CBD products on the market are marijuana derived and contain THC.

Purity levels in CBD-infused products will give an industry advantage to those producers that can utilize the most CBD, without delivering any THC.

Phivida’s nanoencapsulated CBD-Hemp Oil extracts, edibles and infusions, are federally legal, derived from Farm-Bill-compliant farms, and are now 100% WADA-compliant sources for cannabidiol. As well, they’re coming to a store near you.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated eight hundred dollars for its efforts in distributing the Phivida article. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.
]]>
<![CDATA[Valeant (VRX) Cleans Up its Debt]]>Thu, 12 Oct 2017 07:40:19 ESThttp://www.baystreet.ca/articles.aspx?id=38457
Valeant, on October 3, issued a $1-billion debt offering that lower the total upcoming maturities.

Valeant priced its $1-billion principal amount of 5.5% senior notes due in 2025. It will use the proceeds to roll over existing debt. The issuance is not trivial: the lower interest will save the company money while simultaneously pushing out the maturity date.

The low interest rate offered suggests the market has a healthy appetite for Valeant’s debt, so the fear of any bankruptcy is now off the table. Valeant now has around $26 billion in debt and $24 billion net of cash. In June, the company’s net debt was $26.7 billion. The sale of Dendreon raised $811 million, while iNova brought in $923 million. The net effect is that Valeant will have $3.9 billion maturing in 2020.

Assuming Valeant generates $1 billion in free cash flow, the company’s interest on debt in 2020 are covered. It sets the stage for refinancing for the debt due in 2021 and beyond.
]]>
<![CDATA[Athersys Hikes on MultiStem Hookup with Japanese Firm ]]>Wed, 11 Oct 2017 12:24:52 ESThttp://www.baystreet.ca/articles.aspx?id=38456Based on the agreement, Athersys and NCLi will engage in technology transfer activities at NCLi’s facility in Japan, and NCLi will begin contract manufacturing support for commercial development of the product in Japan. Athersys’ collaborator, HEALIOS K.K. (Healios), has an exclusive license to develop and market MultiStem in Japan for ischemic stroke, and is currently conducting its registrational clinical study, TREASURE, in Japan.

A news release issued Wednesday claimed therapeutic treatment with MultiStem may extend the stroke treatment window to 36 hours from the current three to four-and-a-half hours with existing standard of care, which would enable many more stroke patients to receive treatment than under the current standard of care and may also meaningfully enhance patient recovery.
Currently, there are nearly 17 million people that suffer a stroke globally and, on average, someone in the United States has a stroke every 40 seconds.
Athersys shares gained 11 cents, or 4.9%, midday Wednesday to $2.34, within a 52-week trading range of $1.02 to $2.63.
]]>
<![CDATA[Delta Gains Altitude on Q3 Earnings]]>Wed, 11 Oct 2017 11:12:22 ESThttp://www.baystreet.ca/articles.aspx?id=38455The number-two U.S. airline reported adjusted earnings per share of $1.57, beating analysts' expectations of $1.53 a share for a quarter that ended with hurricanes that crippled operations.

Earnings per share were about 8% lower over the year-earlier period.

The airline posted quarterly revenue of $11.06 billion, slightly higher than expectations for $11.03 billion in the three months ended in September.

Delta's passenger revenue per available seat mile — a key income metric — rose 1.9%, in line with the airline's updated forecast earlier last month. It said it expects a 2% to 4% increase in passenger unit revenue in the fourth quarter, but warned that higher fuel costs would likely crimp operating margins for the last three months of the year.

Delta posted higher revenue in domestic and Latin American and trans-Atlantic operations, despite powerful storms in the Southern U.S. in August and September.

Delta executives will likely address the impact from deadly storms that hit carriers' hubs late this summer, as well as a bitter trade dispute between two Delta suppliers, Boeing and Canada's Bombardier.

Hurricane Irma, which struck Florida and Delta's hub in Atlanta, forced the airline to cancel more than 2,000 flights.

Delta shares began Wednesday’s trading up 37 cents to $53.07
]]>
<![CDATA[BlackRock Rocks Markets on Q3 Figures ]]>Wed, 11 Oct 2017 10:42:55 ESThttp://www.baystreet.ca/articles.aspx?id=38454Total assets under management rose 17% to nearly $6 trillion as net inflows easily beat Wall Street expectations.

Here's how the company's results compare to Wall Street's expectations: EPS came in at $5.92 per share, compared with $5.56 expected. Revenue was $3.233 billion versus $3.096 billion expected.

Total assets under management registered at $5.977 trillion versus experts’ projected $5.94 trillion.
Net inflows were $96 billion versus $71.62 billion expected.
BlackRock also said its iShares exchange-traded funds business saw $52.3 billion in long-term net inflows, led by $33.1 billion in equity inflows. Assets under management for iShares totaled $1.640 trillion, accounting for 27% of BlackRock's total assets.

The company said cash assets rose 6 percent from a year earlier to $425.4 billion.

"One of the greatest problems we still have in the world is how much money is sitting on the sideline," according to CEO Larry Fink. "Even in places like Japan, there's $5 trillion in cash earning negative return. In Germany 72% of savings are in bank accounts. We're seeing some of that unlocked (and), we're seeing people put some of that money to work."

The company's stock has been on fire this year, advancing 21.5%. By comparison, the overall S&P 500 is up about 14% in the period. BlackRock shares have also outperformed the financials sector, which is up 13% in 2017.
BlackRock shares opened Wednesday up $2.80 to $468.29 ]]>
<![CDATA[Emblem Positioned to be Disruptive in the Medical Cannabis Industry]]>Wed, 11 Oct 2017 08:44:45 ESThttp://www.baystreet.ca/articles.aspx?id=38453
First, it has become apparent that for the foreseeable future, a few select Canadian marijuana companies will lead the sector growth, particularly over the US.


Second, the virtually unlimited growth in the space will and is being realized through the pharmaceutical developments, particularly in the pain, sleep and anxiety markets. Pain markets alone are $60 billion and will rise over 30% to $83 billion by 2024. Pain and sleep markets are two of the largest component markets.

Key to this growth at companies such as Emblem (TSXV:EMC) is when society embraces marijuana as what could well be the first line of defense and treatment for many afflictions, including the devastating opiate crisis.

“Emblem is focused on developing mainstream medical therapies to deliver consistent, 12-hour relief, with reduced side effects.,” states Gordon Fox, CEO Emblem Corp. “Canada is one of the few jurisdictions in the world –including the USA--with a path to regulatory approval of cannabinoid based medication. ACMPR has mechanisms for approval and these mechanisms are currently being expanded. The Canadian medical community can participate in research and clinical trials and share data and results across provincial boundaries.

With our recently announced exclusive arrangement with CanntabTherapeutics, Emblem is executing to plan.”

The Canntab Deal

Very simply, Canntab has the proprietary sustained release formulation: Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marijuana.

Canada is one of the few jurisdictions in the world with a path to regulatory approval of cannabinoid based medication.

- The current medical cannabis market in Canada is about $400 million. It is searching for better dosage formats. Simple oils have grown to about 35% of the market in less than a year. More appropriate dosage formats are expected to have comparable effects in the market.

- Currently, Cannabis tends to require re-dosing. A titratable, sustained release formulation would have substantial appeal in the chronic neuropathic pain market. Anecdotally, that segment represents a reasonable percentage of the current$400 million medical cannabis market.

- The Canadian non-cannabis chronic pain pharmaceutical market is over $500 million and dominated by opioids and is expected to reach $42.16 billion worldwide by 2021. A cannabinoid based sustained release product has potential to enter that market.



From Emblem’s October 3rd Press Release:

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use.

The Agreement grants to Emblem the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing, commercializing, using, selling, and offering the Sustained Release Product for sale under the Emblem brand. The License does not include the right to import or export the Product. The Sustained Release Products will be manufactured by Emblem or by Canntab, after Canntab receives appropriate licensing allowing such manufacture.

As per other Royalty Agreements in the Pharmaceutical Sector terms weren’t disclosed other than ‘double digit” royalty. To be clear this relationship with Canntab is extremely favorable to Emblem.

It cannot be overstated how important a develop this is for patients. Instead of waiting 5-10 years for a therapy to get to patients, cannabis based products take mere months. There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including (i) chronic pain (ii) nausea, (iii) anxiety and sleep disorders, and (iv) spasticity in patients with Multiple Sclerosis.

The Global Opiate Crisis

While therapies will address particular conditions, anecdotally many patients know and have expressed the efficacy, ease of use and lack of side effects in pain management particularly.

Emblem plans to bring products to deal with neurological pain by fall 2018. Once the 12- hour delivery protocol is established, many afflictions can be addressed via the proper strain and titration.

Investors need to embrace the potential of this market and acquire some exposure. Choose carefully as there are many companies who have and will likely fail or price themselves out of the market.

Emblem’s business plan sets three divisions to be profit centres. From ongoing reasonable to maximum growth:

- Dried flower is the commodity space which provides superior, but generic product

- High quality strains (think aged single malt scotch versus JW Black) for the aficionado

- Top quality strains for ongoing therapeutics’ development.

Margins increase exponentially from dried flower to medical strains. Emblem (TSXV:EMC) is focused on the two markets above dried flower, although will be a major force in all three.

Marijuana Market Maturing Slightly. Invest Carefully, but Invest

The Marijuana space has matured somewhat from mining guys seeing a quick turn in fortunes by announcing some hair-brained participation to get their languishing stock prices up.

Then there the companies who conclude that more marijuana is better and are growing as much as they can.

Finally, there are a few companies, such as Emblem that have a solid growth plan and are not afraid to state their corporate intentions. Many comparisons are made to the UK’s GW Pharma as the direction a developing company should travel.

GW’s Sativex is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. GW’s ADS on NASDAQ in 2013 came at $8.90. Last trade at this writing was $114.07.

Fun Facts

- Some plant biologists got their early weed (60’s, 70’s) experience by serving time for possession, etc.

- Lots of anecdotal evidence that Big Pharma continues to pay doctors to keep their products at the forefront

The five companies that disclosed what they paid doctors over a six-month period (July to December 2016) were:

- AbbVie (NYSE:ABBV) : $4,104,000

- Novartis (NYSE:NVS) : $3,645,026

- Amgen (NASDAQ:AMGN) : $2,365,000

- Bristol-Myers Squibb (NYSE:BMY) : $1,388,187

- Gilead (NASDAQ: GILD) : $539,761



That alone should give Marijuana companies such as Emblem a place in your speculative portfolio.

Oh, yes. 10 percent of patients suffer from Trypanophobia. That fear keeps 20 percent of that number to never seek medical attention. Look it up…

Perhaps with the inevitable insertion of Marijuana based therapies should reduce or eliminate that number.

And how would Big Pharma ‘payola’ doctors for such a readily available and efficacious therapy? Bueller?

Next couple of decades should be interesting; with less pain, more sleep, relief from chronic disease as well as lives saved.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated four thousand dollars for its efforts in distributing the TSXV:EMC profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[AnaptysBio Makes Waves on Trial Data ]]>Tue, 10 Oct 2017 03:25:01 ESThttp://www.baystreet.ca/articles.aspx?id=38452Said CEO Hamza Suria, “we are very encouraged by the efficacy results to date in this Phase 2a study, which exemplify our strategic focus on developing first-in-class anti-inflammatory antibody therapeutics to help patients suffering from debilitating inflammatory diseases.

“We look forward to further advancing the development of ANB020 for the treatment of patients with atopic diseases.”

The Phase 2a study is currently ongoing and EASI scores will be assessed for each patient up to 140 days post-ANB020 treatment. The company plans to report full data from this trial at a medical conference following study completion.

AnaptysBio is a clinical-stage biotechnology company developing what it calls “first-in-class antibody product candidates focused on unmet medical needs in inflammation”.

Its shares neared the close Tuesday up in the stratosphere, leaping in price $31.02, or 88.6%, to $66.02.
]]>
<![CDATA[Wal-Mart Hikes on Share Buyback Program]]>Tue, 10 Oct 2017 11:30:29 ESThttp://www.baystreet.ca/articles.aspx?id=38451Wal-Mart also unveiled a $20-billion share repurchase program to replace its existing plan. The company says the new authorization will be used over a two-year period.

The big-box retailer explained it will continue to focus on remodeling existing stores and incorporating "digital experiences" in place of building new locations.

Ahead of its annual investor day in Bentonville, Arkansas, Wal-Mart said it expects its U.S. e-commerce business to grow sales by roughly 40% in fiscal 2019. Online transactions surged 60% during the second quarter of this year, the retailer declared in August.

The company still expects adjusted earnings per share for the fiscal year 2018 to fall between $4.30 and $4.40.

For fiscal 2019, Wal-Mart said it expects earnings to increase about 5% year over year. Net sales for fiscal 2019 are expected to grow close to 3%, driven by same-store and e-commerce sales growth, the company added.

In fiscal 2019, across the U.S., Walmart will open fewer than 15 Supercenters and fewer than 10 of its Neighborhood Markets.

For fiscal years 2018 and 2019 combined, Wal-Mart is calling for capital expenditures to be about $11 billion, with e-commerce investments going toward enhancing the retailer's supply chain. Wal-Mart's international business will also invest more in fulfillment capabilities.

Shares in Wal-Mart galloped $3.53, or 4.4%, to $84.06
]]>